 |
 |
The Mark-C test: message from the company
NeuroMark congratulates scientists from the Genetic Basis of Mood and Anxiety Disorders Unit and the Laboratory of Molecular Pathophysiology, Mood and Anxiety Program, National Institute of Mental Health, Bethesda, MD; Departments of Clinical Sciences and Psychiatry, University of Texas Southwestern Medical Center, Dallas; Genometrics Section, Inherited Disease Research Branch, National Human Genome Research Institute, NIH, Baltimore; and Mount Sinai School of Medicine, New York, on their precedent-setting discoveries of genetic markers of suicidal ideation emerging during citalopram treatment of major depression.
We are pleased to announce the planning and development of two separate confirmatory trials for the first genetic test – the Mark-C test – for this potentially dangerous adverse event. One study in preparation is to be conducted independently at a world-renowned research institute. The second study is being sponsored by NeuroMark. It will be a prospective study, and we are planning for it to be open to selected physicians and patients who wish to participate using the Mark-C test on an Investigational Use Only basis. If you are interested in applying to participate in the study, please send an email to study@neuromark.com for more information. Other than within the NeuroMark confirmatory study, the test is not commercially available at this time. After analyzing the data from the confirmatory studies we will announce when the test will become available.
We appreciate the strong interest we have received in the test and the potential clinical value for those prescribing the widely-used citalopram family of antidepressant drugs. We assure you that we are working diligently to make the test one in which the physician will have confidence and one that encourages patients who are experiencing depression to seek treatment.
Kim Bechthold
CEO, NeuroMark
NeuroMark congratulates scientists from the Genetic Basis of Mood and Anxiety Disorders Unit and the Laboratory of Molecular Pathophysiology, Mood and Anxiety Program, National Institute of Mental Health, Bethesda, MD; Departments of Clinical Sciences and Psychiatry, University of Texas Southwestern Medical Center, Dallas; Genometrics Section, Inherited Disease Research Branch, National Human Genome Research Institute, NIH, Baltimore; and Mount Sinai School of Medicine, New York, on their precedent-setting discoveries of genetic markers of suicidal ideation emerging during citalopram treatment of major depression.
We are pleased to announce the planning and development of two separate confirmatory trials for the first genetic test – the Mark-C test – for this potentially dangerous adverse event. One study in preparation is to be conducted independently at a world-renowned research institute. The second study is being sponsored by NeuroMark. It will be a prospective study, and we are planning for it to be open to selected physicians and patients who wish to participate using the Mark-C test on an Investigational Use Only basis. If you are interested in applying to participate in the study, please send an email to study@neuromark.com for more information. Other than within the NeuroMark confirmatory study, the test is not commercially available at this time. After analyzing the data from the confirmatory studies we will announce when the test will become available.
We appreciate the strong interest we have received in the test and the potential clinical value for those prescribing the widely-used citalopram family of antidepressant drugs. We assure you that we are working diligently to make the test one in which the physician will have confidence and one that encourages patients who are experiencing depression to seek treatment.
Kim Bechthold
CEO, NeuroMark